Spinal, Peripheral and PLMS Mechanisms in Restless Legs Syndrome

Medical disclaimer: this is a research synthesis, not medical advice. RLS is a chronic neurological condition; nothing here claims a "cure." Dopamine-agonist and alpha-2-delta-ligand tapering must only be done under physician supervision - never stop abruptly. See docs/00_MASTER_PLAN.md Section 2.

This synthesis covers the evidence on spinal cord hyperexcitability, peripheral (nerve, vascular, autonomic) contributions, and the physiology/consequences of periodic limb movements in sleep (PLMS) in RLS/Willis-Ekbom disease. It draws on 29 newly written study notes plus 16 pre-existing notes in this knowledge base that other research sweeps had already produced on directly overlapping ground (TMS/cortical excitability, PLM-arousal physiology, cardiovascular epidemiology, and the adenosine hypothesis).

What is established (grade A/B)

• A meta-analysis of 6 studies found PLMS carriers have significantly higher rates of coronary artery disease (OR 1.57, 95% CI 1.19-2.07, p=0.002) and cardiovascular disease overall (OR 1.28, 95% CI 1.10-1.49, p=0.002), though not acute MI specifically (grade A; 2018-huang-plms-cardiovascular-meta-analysis.md, PMID 29952124).
• In the large prospective MrOS cohort (n=2,911 older men, 4.4-year follow-up), higher PLMS and PLMS-arousal indices independently predicted incident all-cause cardiovascular disease (+25-31%) and roughly a 2-fold increase in incident peripheral arterial disease, but not incident hypertension (grade B; 2011-koo-mros-plms-cardiovascular.md, PMID 21859975).
• Each individual PLMS event triggers an acute surge in heart rate and blood pressure (on the order of 10-20 mmHg / ~10 bpm per the MrOS review), significantly larger in RLS patients than in healthy controls (grade B; 2013-pennestri-plms-blood-pressure-surges.md, PMID 23643655).
• The spinal flexor reflex (FR) is hyperexcitable and state-dependent (worse in sleep) in RLS/PLMS, a finding replicated in secondary, uremic RLS - establishing PLMS as at least partly a spinal-generator phenomenon under descending dopaminergic control (grade B/C; 2000-bara-jimenez-spinal-flexor-reflex.md PMID 10762502; 2002-aksu-flexor-reflex-renal-failure.md PMID 14592176).
• Peripheral leg-specific hypoxia occurs during enforced immobility in RLS, scales with symptom severity, and is partially reversed by pramipexole (grade B; 2014-salminen-peripheral-hypoxia-rls.md, PMID 24789861).
• Cardiovagal baroreflex gain is reduced and leg vascular resistance increased in RLS patients without overt cardiovascular disease, at similar resting BP/HR to controls (grade B; 2016-bertisch-baroreflex-cardiovascular-control.md, PMID 26564128).
• A pharmacological double dissociation RCT showed a dopamine agonist suppresses PLMS without normalizing cortical EEG arousal instability, while clonazepam does the reverse - proving PLMS and cortical arousal are at least partially separable mechanisms (grade B; pre-existing note 2012-manconi-plm-arousal-dissociation-rct.md, PMID 22718547).
• Population-level meta-analyses tie RLS to hypertension (pooled OR 1.36, 9 studies, 102,408 people) and to significantly higher adjusted all-cause mortality (HR 1.52), although adjusted cerebro/cardiovascular event risk specifically loses significance after confounder adjustment (grade A; pre-existing notes 2017-shen-meta-analysis-hypertension-risk.md PMID 29134444, 2017-katsanos-meta-analysis-cardiovascular-mortality.md PMID 28948600).
• A systematic review of 21 pooled TMS studies (319 RLS patients, 278 controls) found reduced short-interval intracortical inhibition (SICI) - a GABAergic cortical marker - as the single most reproducible neurophysiological abnormality in RLS (grade A; pre-existing note 2024-lanza-systematic-review-motor-cortex-tms.md, PMID 39626363).
• The 2025 AASM clinical practice guideline gives a conditional, moderate-certainty recommendation for bilateral high-frequency peroneal nerve stimulation - the only device-based peripheral-nerve non-drug therapy it endorses - alongside strong recommendations for iron repletion and alpha-2-delta ligands and recommendations against standard-use dopamine agonists (grade D but institutionally authoritative; pre-existing note 2025-winkelman-aasm-guideline-rls.md, PMID 39324694).

Emerging C

• Skin biopsies show increased cutaneous adrenergic nerve fiber density and altered capillary endothelial maturity (elevated CD105:CD31 ratio) in RLS, consistent with sympathetic hyperactivity plus a hypoxia-driven vascular remodeling response (2021-bergmann-skin-biopsy-sympathetic.md, PMID 34174707).
• Systemic vascular endothelial dysfunction (reduced brachial-artery flow-mediated dilatation) is present in drug-naive RLS patients and correlates with severity (2015-koh-endothelial-dysfunction-rls.md, PMID 26671114).
• RLS is common in small-fiber-predominant, often acquired/dysimmune polyneuropathy (30% prevalence) and in diabetic/prediabetic neuropathy (33% prevalence), and nociceptive deafferentation from small-fiber loss is hypothesized as a trigger for spinal RLS "generators" (2006-gemignani-polyneuropathy-rls.md PMID 16685701; 2007-gemignani-diabetic-neuropathy-rls.md PMID 17374101; 2009-gemignani-painful-neuropathy-deafferentation.md PMID 20021603).
• TMS studies show a nighttime-specific drop in active motor threshold matching circadian symptom worsening, partial restoration of disrupted cortical plasticity by dopaminergic treatment, impaired LTD-like plasticity, and SICI reduction that scales with severity and discriminates RLS from controls (2012-gunduz-circadian-cortical-excitability.md PMID 22305328; 2010-scalise-dopaminergic-cortical-plasticity.md PMID 19595629; pre-existing 2018-lanza-impaired-ltd-plasticity-rtms.md PMID 29773202; pre-existing 2019-magalhaes-sici-severity.md PMID 31539846).
• A small double-blind pilot RCT found high-frequency rTMS over the supplementary motor area significantly improved IRLS severity scores versus sham (2014-altunrende-rtms-restless-legs-rct.md, PMID 24487701).
• Drug-naive RLS patients report elevated autonomic symptom burden across multiple SCOPA-AUT domains correlating with severity, and show a blunted sympathovagal (LF/HF) response to orthostatic stress while awake (2021-basaran-autonomic-scopa-rls.md PMID 34871924; 2021-shin-hrv-orthostatic-rls.md PMID 33438574).
• A time-locked EEG/heart-rate activation cascade precedes PLM onset regardless of whether a microarousal is scored, supporting a shared brainstem-to-cortex activation model rather than simple PLM-causes-arousal (pre-existing 2002-sforza-cerebral-autonomic-plm-arousal.md, PMID 12048047).
• Population-based polysomnography (n=2,162) finds PLMSI>15 in 28.6% of adults, independently associated with BTBD9, TOX3, and MEIS1 variants as well as age, male sex, BMI, and antidepressant use (pre-existing 2016-haba-rubio-plms-prevalence-genetic-determinants.md, PMID 26703954).
• Objective daytime sleepiness in RLS is specifically tied to PLM-with-arousal burden rather than insomnia alone, challenging the assumption that RLS hyperarousal fully protects against sleepiness (pre-existing 2025-chenini-daytime-sleepiness-arousal-rls.md, PMID 40112236).
• An emerging hypoadenosine/hyperglutamatergic hypothesis proposes adenosine A1-receptor downregulation (driven by brain iron deficiency) as a unifying link between dopaminergic dysfunction, cortical/spinal hyperexcitability, and glutamatergic hyperarousal (2026-baker-emerging-mechanisms-rls.md PMID 42462324; pre-existing 2016-quiroz-adenosine-a1-receptor-downregulation.md PMID 27600688; pre-existing 2025-mogavero-adenosine-hypothesis-critical-review.md PMID 41388724).
• Rodent/primate models (A11 diencephalospinal lesion, iron deprivation, dopamine D3 knockout, aged-rodent dopamine-receptor blockade) reproduce PLMS-like motor behavior, supporting the spinal-dopaminergic mechanism (2007-ondo-animal-models-rls.md, PMID 17468045).
• A circadian-mechanisms review ties peripheral hypoxia and impaired microvascular circulation (elevated HIF-1α/HIF-2α/VEGF, abnormal laser-Doppler and thermographic leg blood flow) to the same evening/night symptom-worsening window as central dopamine/melatonin factors, and notes near-infrared light therapy improves symptoms via nitric-oxide-mediated vasodilation (2023-tang-circadian-rhythm-rls-review.md, PMID 36908590).

Contested or negative findings

• PLMS/PLMS-arousal indices were not associated with incident hypertension in the MrOS cohort after adjustment (2011-koo-mros-plms-cardiovascular.md), and a separate 1,163-patient Korean clinical cohort found no significant PLMI/PLMAI-hypertension association after multivariate adjustment despite a positive unadjusted signal (2018-shin-plms-hypertension-negative.md, PMID 30032284).
• PLMS was not associated with cardiac arrhythmia in the overall MrOS cohort (n=2,793); a positive signal for ventricular tachycardia appeared only in men not taking rate-controlling medication, and for atrial fibrillation only in men with pre-existing structural heart disease (2014-koo-plms-cardiac-arrhythmia.md, PMID 24426814).
• PLMS was not associated with incident atrial fibrillation in the overall cohort of a second MrOS analysis; a positive signal was confined to men aged 76 and older, with wide confidence intervals (2016-may-plms-atrial-fibrillation.md, PMID 27823721).
• After adjusting for confounders, RLS's association with cerebrovascular/cardiovascular events (as opposed to all-cause mortality) lost statistical significance in the largest available meta-analysis (pre-existing 2017-katsanos-meta-analysis-cardiovascular-mortality.md, PMID 28948600).
• No significant difference in nerve conduction studies, heart rate variability, or sympathetic skin response was found between RLS patients and controls in one study, despite patients reporting clear neuropathic/autonomic symptoms - arguing against a fixed peripheral autonomic neuropathy and for a central, transient-arousal-driven explanation instead (2010-isak-autonomic-tests-rls.md, PMID 21138399). This sits in tension with the positive autonomic findings in 2016-bertisch-baroreflex-cardiovascular-control.md, 2021-basaran-autonomic-scopa-rls.md, and 2021-shin-hrv-orthostatic-rls.md (see Open Questions).
• PLMS scoring itself is contested: AASM and WASM/IRLSSG rules disagree, and both appear to overestimate "true" PLMS in obstructive sleep apnea patients relative to an empirically derived respiratory-event window (67%/80% vs 41% of patients classified as PLMSI>15) (2015-manconi-respiratory-leg-movements-definition.md PMID 25325500; 2023-kang-plm-scoring-rules-osa.md PMID 37331132).
• The Manconi 2012 double dissociation is itself a complication for a simple "PLMS causes harm" model: since dopamine agonists abolish PLMS without normalizing EEG arousal instability, PLMS-index reduction alone should not be assumed to fully normalize sleep quality or downstream risk (pre-existing 2012-manconi-plm-arousal-dissociation-rct.md, PMID 22718547).

Mechanistic picture in 5 bullet points

1. A hyperexcitable spinal "final common pathway." Dopaminergically under-inhibited flexor-withdrawal-reflex circuitry generates PLMS via a hyperexcitable segmental spinal generator, demonstrated in both idiopathic and secondary (uremic) RLS, and reproduced in animal models of A11/iron-deficiency dopaminergic loss (2000-bara-jimenez-spinal-flexor-reflex.md; 2002-aksu-flexor-reflex-renal-failure.md; 2007-ondo-animal-models-rls.md).
2. Cortical disinhibition layered on top. Reduced GABAergic short-interval intracortical inhibition, impaired LTD-like plasticity, and a circadian (nighttime-specific) drop in motor threshold together show the motor cortex - not just the spinal cord - loses inhibitory tone in RLS, worst in the evening/night (pre-existing 1999-tergau-motor-system-excitability.md; pre-existing 2024-lanza-systematic-review-motor-cortex-tms.md; 2012-gunduz-circadian-cortical-excitability.md; pre-existing 2019-magalhaes-sici-severity.md).
3. Peripheral hypoxia and microvascular/endothelial dysfunction. Lower leg pO2 on immobilization, reduced flow-mediated dilatation, altered capillary endothelial maturity, and increased cutaneous sympathetic fiber density constitute a parallel, partly dopamine-reversible, peripheral contributor to symptom generation and evening worsening (2014-salminen-peripheral-hypoxia-rls.md; 2015-koh-endothelial-dysfunction-rls.md; 2021-bergmann-skin-biopsy-sympathetic.md; 2023-tang-circadian-rhythm-rls-review.md).
4. Each PLMS is an acute autonomic storm, on a background of impaired tonic autonomic control. Individual PLMS events cause BP/HR surges, and RLS patients independently show reduced baroreflex gain, blunted orthostatic sympathovagal responses, and elevated leg vascular resistance - together a plausible mechanistic bridge to the epidemiological PLMS/RLS-cardiovascular link, although the arrhythmia- and hypertension-specific data are inconsistent (2013-pennestri-plms-blood-pressure-surges.md; 2016-bertisch-baroreflex-cardiovascular-control.md; 2021-shin-hrv-orthostatic-rls.md; 2011-koo-mros-plms-cardiovascular.md; 2018-shin-plms-hypertension-negative.md).
5. RLS/PLMS is mechanistically plural, not one lesion. PLMS and cortical arousal are dissociable outputs of a shared hyperarousal state rather than simple cause-and-effect, and peripheral small-fiber neuropathy/nociceptive deafferentation can independently trigger or mimic the same spinal picture - meaning different patients may reach "RLS" via different dominant mechanisms (pre-existing 2012-manconi-plm-arousal-dissociation-rct.md; pre-existing 2002-sforza-cerebral-autonomic-plm-arousal.md; 2009-gemignani-painful-neuropathy-deafferentation.md; 2006-gemignani-polyneuropathy-rls.md).

Implications for a non-drug long-term plan for people currently on dopamine agonists or alpha-2-delta ligands

None of the following is a substitute for physician-supervised care. Dopamine-agonist tapering must be slow, physician-supervised, and never abrupt, because of augmentation and dopamine-agonist-withdrawal-syndrome (DAWS) risk (master plan Section 2/3).

• Because spinal flexor-reflex hyperexcitability and cortical disinhibition are both normally held in check by dopaminergic and iron-dependent tone (2000-bara-jimenez-spinal-flexor-reflex.md; pre-existing 2024-lanza-systematic-review-motor-cortex-tms.md), any physician-guided taper should be paired with iron repletion to the ferritin/transferrin-saturation targets in the 2025 AASM guideline, so the "excitability brake" does not depend solely on the drug being removed (pre-existing 2025-winkelman-aasm-guideline-rls.md).
• Bilateral high-frequency peroneal nerve stimulation is the one device-based, non-drug therapy with a formal AASM guideline recommendation, and is a reasonable option to discuss with a physician as an adjunct during a taper (pre-existing 2025-winkelman-aasm-guideline-rls.md).
• Repetitive TMS over the supplementary motor area has preliminary randomized evidence of symptom benefit and mechanistically targets the same cortical disinhibition (reduced SICI) documented throughout this topic; it is promising but still early-stage (2014-altunrende-rtms-restless-legs-rct.md; 2016-lanza-central-peripheral-excitability-review.md).
• Interventions that improve peripheral leg perfusion/oxygenation and reduce prolonged immobility - regular daytime exercise, pneumatic compression, avoiding long sedentary periods, and (per the master plan) TOMAC/Nidra-type devices - are mechanistically supported by the peripheral-hypoxia and endothelial-dysfunction literature and plausibly help independent of dopaminergic dosing (2014-salminen-peripheral-hypoxia-rls.md; 2015-koh-endothelial-dysfunction-rls.md; 2023-tang-circadian-rhythm-rls-review.md).
• Because PLMS burden independently predicts incident cardiovascular and peripheral arterial disease (2011-koo-mros-plms-cardiovascular.md) and coronary/CV comorbidity (2018-huang-plms-cardiovascular-meta-analysis.md), a long-term plan should track the PLMS index as a cardiovascular-relevant outcome (not only a comfort metric) - but only after accounting for comorbid sleep apnea, which inflates PLMS counts under standard scoring rules (2015-manconi-respiratory-leg-movements-definition.md; 2023-kang-plm-scoring-rules-osa.md), and treat any comorbid OSA aggressively.
• Graded aerobic exercise (which improves baroreflex sensitivity in other populations) is a reasonable adjunct given the documented baroreflex and orthostatic sympathovagal impairments in RLS (2016-bertisch-baroreflex-cardiovascular-control.md; 2021-shin-hrv-orthostatic-rls.md).
• Screen for and treat contributing peripheral small-fiber neuropathy (glycemic optimization in prediabetes/diabetes, dysimmune-neuropathy workup) in patients whose RLS overlaps with painful or dysesthetic neuropathy, since this may reduce the peripheral drive independent of dopaminergic dosing (2007-gemignani-diabetic-neuropathy-rls.md; 2009-gemignani-painful-neuropathy-deafferentation.md).
• Do not expect PLMS reduction alone to normalize sleep architecture or eliminate cardiovascular risk: PLMS and cortical arousal are separable (pre-existing 2012-manconi-plm-arousal-dissociation-rct.md), so a comprehensive plan should also address sleep continuity/arousal (e.g., comorbid insomnia) alongside PLMS-specific measures.

Open questions

• Does reducing PLMS through non-drug means (iron repletion, exercise, peroneal nerve stimulation, OSA treatment) actually lower long-term cardiovascular event rates, or only the surrogate PLMS index? No interventional trial with hard cardiovascular endpoints exists in this knowledge base; the meta-analysis authors themselves call for this research (2018-huang-plms-cardiovascular-meta-analysis.md).
• Is peripheral hypoxia/microvascular dysfunction a cause, a consequence, or a parallel epiphenomenon of central iron/dopamine dysfunction? Pramipexole reversal of leg hypoxia suggests a link but not a direction (2014-salminen-peripheral-hypoxia-rls.md).
• How much of the "RLS/PLMS-cardiovascular" epidemiological signal is confounded by comorbid, undertreated OSA, given that standard PLMS scoring rules substantially overestimate PLMS in OSA patients (2015-manconi-respiratory-leg-movements-definition.md; 2023-kang-plm-scoring-rules-osa.md)?
• Does long-term rTMS or peroneal nerve stimulation allow measurable dopamine-agonist dose reduction without symptom rebound or augmentation recurrence? No such trial exists yet in this topic; the rTMS RCT is small and short (2014-altunrende-rtms-restless-legs-rct.md) and the guideline rates peroneal nerve stimulation evidence only "moderate" certainty (pre-existing 2025-winkelman-aasm-guideline-rls.md).
• What is the true prevalence and clinical significance of concomitant small-fiber neuropathy in idiopathic (non-neuropathy-associated) RLS, and does treating an incidental SFN measurably reduce RLS/PLMS severity? (2006-gemignani-polyneuropathy-rls.md; 2021-bergmann-skin-biopsy-sympathetic.md).
• Does the hypoadenosine/hyperglutamatergic hypothesis translate into an effective, dopamine-agonist-sparing therapy? The dipyridamole/caffeine "pharmaco-TMS" biomarker approach is only a published protocol so far, without results (pre-existing 2024-lanza-tms-pharmaco-protocol-dipyridamole-caffeine.md; 2026-baker-emerging-mechanisms-rls.md).
• Why do autonomic-function findings diverge - one screening study found no peripheral autonomic neuropathy signal (2010-isak-autonomic-tests-rls.md), while others found reduced baroreflex gain, elevated SCOPA-AUT scores, and blunted orthostatic sympathovagal responses (2016-bertisch-baroreflex-cardiovascular-control.md; 2021-basaran-autonomic-scopa-rls.md; 2021-shin-hrv-orthostatic-rls.md)? This may reflect differences between coarse screening tests and quantitative autonomic physiology, or genuine population heterogeneity, and needs a head-to-head study.
• Given the "painful legs and moving toes" and related literature suggesting some RLS-adjacent spinal/peripheral movement syndromes can follow focal nerve or spinal trauma, how distinct are these secondary phenocopies from idiopathic RLS mechanistically, and does that matter for treatment choice? (referenced in 2016-lanza-central-peripheral-excitability-review.md).

Notes in this topic

New notes written for this sweep:

• 2000-bara-jimenez-spinal-flexor-reflex.md - Landmark finding that the spinal flexor reflex is hyperexcitable and state-dependent in RLS/PLMS (PMID 10762502).
• 2002-aksu-flexor-reflex-renal-failure.md - Replicates spinal flexor-reflex hyperexcitability in secondary (uremic) RLS (PMID 14592176).
• 2013-pennestri-plms-blood-pressure-surges.md - Each PLMS event triggers a BP/HR surge, larger in RLS than in healthy controls (PMID 23643655).
• 2014-salminen-peripheral-hypoxia-rls.md - Leg-specific peripheral hypoxia during immobility, reversed by pramipexole (PMID 24789861).
• 2021-bergmann-skin-biopsy-sympathetic.md - Increased cutaneous sympathetic fibers and altered capillary endothelium in RLS skin (PMID 34174707).
• 2015-koh-endothelial-dysfunction-rls.md - Reduced systemic flow-mediated dilatation in drug-naive RLS (PMID 26671114).
• 2015-manconi-respiratory-leg-movements-definition.md - AASM/WASM PLMS scoring rules both overestimate PLMS in OSA patients (PMID 25325500).
• 2023-kang-plm-scoring-rules-osa.md - Manual vs automated AASM/WASM scoring of leg movements in OSA (PMID 37331132).
• 2019-calzetti-small-fiber-premotor-parkinson.md - Non-length-dependent small fiber pathology in RLS emerging during pre-motor Parkinson's disease (PMID 31439483).
• 2007-gemignani-diabetic-neuropathy-rls.md - RLS frequent in diabetic/prediabetic small fiber neuropathy (PMID 17374101).
• 2006-gemignani-polyneuropathy-rls.md - RLS in polyneuropathy linked to small-fiber, acquired/dysimmune etiology (PMID 16685701).
• 2009-gemignani-painful-neuropathy-deafferentation.md - Nociceptive deafferentation hypothesis for RLS in painful neuropathy (PMID 20021603).
• 2010-isak-autonomic-tests-rls.md - No objective peripheral autonomic neuropathy found despite subjective symptoms (PMID 21138399).
• 2016-bertisch-baroreflex-cardiovascular-control.md - Reduced baroreflex gain and higher leg vascular resistance in RLS (PMID 26564128).
• 2011-koo-mros-plms-cardiovascular.md - Large MrOS cohort: PLMS predicts incident CVD/PAD but not hypertension (PMID 21859975).
• 2018-huang-plms-cardiovascular-meta-analysis.md - Meta-analysis: PLMS associated with coronary artery disease and CVD (PMID 29952124).
• 2018-shin-plms-hypertension-negative.md - Negative: PLMS not independently associated with hypertension in a Korean cohort (PMID 30032284).
• 2014-koo-plms-cardiac-arrhythmia.md - Largely negative: PLMS not linked to arrhythmia except in specific subgroups (PMID 24426814).
• 2016-may-plms-atrial-fibrillation.md - Largely negative: PLMS not linked to incident AF except in men ≥76 (PMID 27823721).
• 2007-ondo-animal-models-rls.md - Review of rodent models (A11 lesion, iron deprivation, D3 knockout) of RLS/PLMS (PMID 17468045).
• 2023-tang-circadian-rhythm-rls-review.md - Review tying peripheral hypoxia/microvascular dysfunction to circadian symptom pattern (PMID 36908590).
• 2015-magalhaes-tms-cortical-excitability-review.md - Systematic review: reduced SICI is the most consistent TMS finding in RLS (PMID 26429756).
• 2012-gunduz-circadian-cortical-excitability.md - Nighttime-specific drop in motor threshold in RLS (PMID 22305328).
• 2010-scalise-dopaminergic-cortical-plasticity.md - Dopaminergic treatment partially restores disrupted cortical plasticity (PMID 19595629).
• 2014-altunrende-rtms-restless-legs-rct.md - Pilot double-blind RCT: rTMS improves RLS severity vs sham (PMID 24487701).
• 2016-lanza-central-peripheral-excitability-review.md - Integrative review of central+peripheral excitability as a network disorder in RLS (PMID 27745789).
• 2026-baker-emerging-mechanisms-rls.md - 2026 review proposing a hypoadenosine/hyperglutamatergic unifying hypothesis (PMID 42462324).
• 2021-basaran-autonomic-scopa-rls.md - Elevated autonomic symptom burden (SCOPA-AUT) in drug-naive RLS (PMID 34871924).
• 2021-shin-hrv-orthostatic-rls.md - Blunted sympathovagal response to orthostatic stress in drug-naive RLS (PMID 33438574).

Pre-existing notes (found already in the knowledge base, written for other topic sweeps, directly relevant here):

• 2002-sforza-cerebral-autonomic-plm-arousal.md - EEG/heart-rate activation cascade precedes PLM onset regardless of arousal scoring (PMID 12048047).
• 2012-manconi-plm-arousal-dissociation-rct.md - Pharmacological double dissociation: dopamine agonist fixes PLMS, clonazepam fixes arousal instability (PMID 22718547).
• 2016-haba-rubio-plms-prevalence-genetic-determinants.md - Population PLMS prevalence (28.6%) and genetic determinants (BTBD9, TOX3, MEIS1) (PMID 26703954).
• 1999-tergau-motor-system-excitability.md - Early TMS study: reduced intracortical inhibition across the motor cortex in RLS (PMID 10102429).
• 2018-lanza-impaired-ltd-plasticity-rtms.md - Impaired LTD-like cortical plasticity via low-frequency rTMS in RLS (PMID 29773202).
• 2019-magalhaes-sici-severity.md - SICI reduction scales with severity and discriminates RLS from controls (PMID 31539846).
• 2024-lanza-systematic-review-motor-cortex-tms.md - Systematic review (21 studies): reduced SICI is the most consistent TMS finding (PMID 39626363).
• 2024-lanza-tms-pharmaco-protocol-dipyridamole-caffeine.md - Pilot "pharmaco-TMS" protocol probing the adenosine system in RLS (PMID 38728342).
• 2012-li-nurses-health-study-coronary-heart-disease.md - RLS duration ≥3 years linked to increased coronary heart disease risk in women (PMID 22967852).
• 2017-katsanos-meta-analysis-cardiovascular-mortality.md - Meta-analysis: RLS linked to higher adjusted all-cause mortality, not adjusted CV events (PMID 28948600).
• 2017-shen-meta-analysis-hypertension-risk.md - Meta-analysis: RLS associated with higher hypertension prevalence (PMID 29134444).
• 2016-molnar-veterans-cohort-mortality-comorbidity.md - Veterans cohort: incident RLS linked to markedly higher mortality, CHD, stroke, CKD (PMID 26377112).
• 2016-quiroz-adenosine-a1-receptor-downregulation.md - Brain iron deficiency downregulates adenosine A1 receptors in animal models (PMID 27600688).
• 2025-mogavero-adenosine-hypothesis-critical-review.md - Critical review of the adenosine hypothesis unifying iron/dopamine/glutamate pathways (PMID 41388724).
• 2025-chenini-daytime-sleepiness-arousal-rls.md - Objective daytime sleepiness in RLS tied to PLM-with-arousal burden (PMID 40112236).
• 2025-winkelman-aasm-guideline-rls.md - 2025 AASM guideline: iron thresholds, drug recommendations, and peroneal nerve stimulation (PMID 39324694).

Additional linked notes (2026-09 quality pass)

These notes carry this topic tag but are not yet woven into the prose synthesis above; listed here so they are discoverable and counted in catalog.json rather than orphaned.

• 2007-etzioni-movement-disorders-sleep-hebrew.md (2007) - [Movement disorders in sleep]: This Hebrew-language review by Etzioni and Pillar (Sleep Lab, Meyer Children's Hospital, Rambam Medical Center and Technion, Haifa, Israel), published in the Israeli Medical Association journal Harefuah, describes mov...
• 2023-riccardi-plms-pharmacological-metaanalysis.md (2023) - Pharmacological responsiveness of periodic limb movements in patients with restless legs syndrome: a systematic review and meta-analysis: In this pre-registered systematic review/meta-analysis (Italian/Swiss group, Lugano and Oasi Research Institute, Troina), dopamine agonists (pramipexole, ropinirole) were the most effective drug class at suppressing p...